The company released its 2016 semi-annual report, with revenue growth of 44.7% to 428 million yuan, and net profit attributable to mothers increased by 44.5% to 63.358 million yuan. Realized earnings per share of 0.15 yuan.
Core view
Smart medical and RFID businesses are growing at a high speed. The company's financial expenses have increased by 21 million compared with the first half of 2015 due to the payment of the medical technology acquisition and the increase in the number of shares. In terms of revenue growth, EAS business decreased by 11% to 190 million, RFID business increased by 56% to 100 million, EAS and RFID revenue increased by 5%, and gross profit increased by 8%. Assuming that the profit growth of 10%-15% of Zhongruisi, plus financial expenses (considering the income tax rate), the profit growth rate of Medical Technology in the first half of the year is more than 60%. We believe that the high growth of smart medical and RFID businesses is expected to continue, providing guarantees for the full-year performance.
The strategy and business are making great strides, and we are firmly optimistic in the long run. In terms of strategy, the management structure of the company's business unit has been continuously optimized, and the two business divisions of “Yuhui Technology†and “Business Intelligence†have been established to strengthen the company's influence in the “Internet + Internet of Things†field. In terms of business: 1>Build a “big open platform + professional miniaturization application†through hybrid cloud to lay the foundation for hospital big data application; 2> extend the company's layout in cognitive computing, and jointly invest its company in the form of localized IBM Watson for the first time. Introduced domestic medical institutions; 3> Newly developed a variety of medical information consumable products, its smart bed products have been rapidly promoted in nursing homes and families, and information collection and opening through the “Smart Family Doctor†IoT platform. The company's strategy is striding forward, and its business is scarce, and it is expected to become the leading company in the field of smart medical care in the next few years.
There is still some uncertainty in the short-term private placement. The company will not initiate a non-public offering if the issue price is always lower than 70% of the average stock price of the 20 trading days prior to the issuance period. We believe that this clause will have a certain repressive effect on the company's short-term share price, and it will also cause certain uncertainty in the company's annual performance and follow-up business promotion time.
Financial forecasting and investment construction
We forecast the company's EPS for 2016-2018 to be 0.54, 0.71, and 0.90, respectively. Among them, Medical Hui Technology contributed EPS of 0.27, 0.38 and 0.49 in 2016-2018. According to the segment valuation method, the smart medical business in 2016 was given 81 times PE, the traditional business was 71 times PE, and the target price was 41.08, maintaining the buy rating.
risk warning
The progress of smart medical and RFID business is not up to expectations, and the artificialization of artificial intelligence is not up to expectations.
PCR ( Polymerase Chain Reaction)
It provides a way to make more copies of a portion of DNA.
We need to have PCR ingredients that include DNA portion, Buffer solution, Primer+DNA (tap polymerase), and Nucleotides during the preparation step.
In the step of PCR sequence, there are three steps in this section.
Step 1 Denaturation
The addition of heat is needed to separate the two strands of the DNA molecule.
Step 2 Annealing
Temperature, is going to be cool in this step, should allow the primers to bind to the specific segments.
Step 3 DNA Synthesis
To make more copies of the DNA.
Those three steps above keep repeating to make enough copies of the DNA fragments. It is the principle of how PCR machine works.
Superyears General 2215 RT-qPCRadopts all-in-one with an industrial art design, combining the Analytical Instrument, Large touch screen, and Computer. General 2215 RT-qPCR is equipped with the proven thermal-cooled electric technology, which can recognize the speed rate of temperature control faster and obtain high-quality testing results within 40 minutes. To ensure the sensitivity and stability of the testing a design with traditional beam path with a susceptible CMOS image sensor is used. In addition, General 2215 supports multiple PCR analysis and High-resolution Melt Curve (HRM) analysis, compatible with the mainstream reagent kit in the market. It will be the best assistant and your preferred RT-qPCR.
Real-Time Pcr Instrument,Real Time Pcr Machine,Real-Time Ploymerase Chain Reaction,5 Channel Real-Time Pcr Instrument
Nanjing Superyears Gene Technology Co., Ltd. , https://www.superyearsglobal.com